Critical Therapeutics starts Zyflo CR study

Critical Therapeutics Inc. today announced the enrollment of the first patient in a new study designed to evaluate Zyflo CR, the name for an extended-release tablet for the treatment of asthma.

The Lexington company focuses on developing and commercializing products for respiratory, inflammatory, and critical care diseases.

The company described the test as a Phase IV clinical study, which will assess the effect of Zyflo CR on lung function, asthma control, and symptomatic response in adult patients whose asthma has not responded to moderate doses of inhaled corticosteroids, another asthma treatment.

Zyflo CR was approved by the Food and Drug Administration on May 30, the company noted.
(Chris Reidy, Globe staff)